|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-24
|
|
pubmed:abstractText |
Neoadjuvant chemotherapy is being increasingly used in operable breast cancer. There are limited data on the safety of bevacizumab (bev) in the neoadjuvant setting. We sought to explore the safety of neoadjuvant cisplatin/bev in a protocol for triple negative breast cancer (TNBC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1534-4681
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
733-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20882415-Adult,
pubmed-meshheading:20882415-Aged,
pubmed-meshheading:20882415-Antibodies, Monoclonal,
pubmed-meshheading:20882415-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20882415-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20882415-Breast Neoplasms,
pubmed-meshheading:20882415-Chemotherapy, Adjuvant,
pubmed-meshheading:20882415-Cisplatin,
pubmed-meshheading:20882415-Combined Modality Therapy,
pubmed-meshheading:20882415-Female,
pubmed-meshheading:20882415-Humans,
pubmed-meshheading:20882415-Middle Aged,
pubmed-meshheading:20882415-Neoadjuvant Therapy,
pubmed-meshheading:20882415-Neoplasm Recurrence, Local,
pubmed-meshheading:20882415-Neoplasm Staging,
pubmed-meshheading:20882415-Postoperative Complications,
pubmed-meshheading:20882415-Receptor, erbB-2,
pubmed-meshheading:20882415-Receptors, Estrogen,
pubmed-meshheading:20882415-Receptors, Progesterone,
pubmed-meshheading:20882415-Sentinel Lymph Node Biopsy,
pubmed-meshheading:20882415-Survival Rate,
pubmed-meshheading:20882415-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Does neoadjuvant bevacizumab increase surgical complications in breast surgery?
|
|
pubmed:affiliation |
Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. mgolshan@partners.org
|
|
pubmed:publicationType |
Journal Article
|
